Table 2.
Estimated number of adult-equivalent doses by World Bank Country income classification (97 countries, 2012–2019).
| Drug (Dosage form) | Estimated number of adult-equivalent dosesb |
||||
|---|---|---|---|---|---|
| HIC | UMIC | LLMIC | Regionala | Total | |
| Asparaginase (IV) | 603,922 | 1,264,706 | 428,431 | 238 | 2,297,297 |
| Bleomycin (IV) | 11,890,300 | 9,187,429 | 7,590,894 | 1200 | 28,669,824 |
| Carboplatin (IV) | 13,432,005 | 5,544,250 | 2,553,904 | 4618 | 21,534,778 |
| Cisplatin (IV) | 13,644,515 | 15,701,673 | 3,378,593 | 8498 | 32,733,279 |
| Cyclophosphamide (IV) | 16,059,863 | 13,459,110 | 2,515,115 | 12,770 | 32,046,858 |
| Cytarabine (IV) | 4,192,125 | 2,121,828 | 394,152 | 533 | 6,708,638 |
| Dacarbazine (IV) | 2,736,444 | 1,186,689 | 244,061 | 358 | 4,167,551 |
| Dactinomycin (IV) | 161,413 | 248,472 | 39,471 | – | 449,357 |
| Daunorubicin (IV) | 815,866 | 780,922 | 176,756 | 163 | 1,773,708 |
| Doxorubicin (IV) | 11,140,778 | 5,203,585 | 1,984,311 | 15,400 | 18,344,074 |
| Etoposide (IV) | 16,883,987 | 12,902,134 | 1,768,036 | 4802 | 31,558,959 |
| Idarubicin (IV) | 583,735 | 404,770 | 14,515 | 44 | 1,003,064 |
| Ifosfamide (IV) | 5,681,916 | 3,774,132 | 566,580 | 270 | 10,022,898 |
| Mercaptopurine (tab) | 192,268,861 | 19,340,329 | 10,526,248 | 5909 | 222,141,347 |
| Methotrexate (IV) | 5,355,806 | 2,398,830 | 748,935 | 1500 | 8,505,071 |
| Methotrexate (tab) | 402,739,733 | 126,013,883 | 114,410,730 | 1,347,432 | 644,511,778 |
| Pegaspargase (IV) | 162,308 | 187,837 | – | – | 350,145 |
| Procarbazine (IV) | 6,103,249 | 823,475 | 466,319 | – | 7,393,043 |
| Rituximab (IV) | 16,879,789 | 2,463,701 | 318,450 | 4934 | 19,666,873 |
| Thiotepa (IV) | 60,750 | 1178 | – | – | 61,928 |
| Thioguanine (tab) | 3,172,992 | 217,120 | 121,341 | – | 3,511,453 |
| Vincristine (IV) | 6,830,591 | 4,133,413 | 1,134,354 | 11,569 | 12,109,926 |
HIC: high income countries; UMIC: upper middle income countries; LLMIC: low and lower middle income countries; IV: intravenous; tab: tablet; IU: international unit; kg: kilogram; g: gram.
Source: This is based on internal analysis by Catherine Habashy, Tatenda Yemeke, Nancy Bolous, Yichen Chen, Sachiko Ozawa, Nickhill Bhakta, and Thomas Alexander using data from the following source: IQVIA MIDAS Quarterly Sales for the period 2012–2019 reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.
Regional category comprised of the Central America region (Guatemala, Honduras, El Salvador, Nicaragua, Costa Rica, and Panama) and the French West Africa region (Benin, Burkina Faso, Cameroon, Chad, Gabon, Guinea, Ivory Coast, Mali, Niger, Republic of the Congo, Senegal, and Togo).
Estimated number of adult doses calculated using BSA of 1.7 m2 and the following dosages: Asparaginase 6000 IU/m2; Bleomycin 10 USP/m2; Carboplatin 400 mg/m2; Cisplatin 75 mg/m2; Cyclophosphamide 750 mg/m2; Cytarabine 2000 mg/m2; Dacarbazine 375 mg/m2; Dactinomycin 1000 mcg/m2; Daunorubicin 45 mg/m2; Doxorubicin 50 mg/m2; Etoposide 100 mg/m2; Idarubicin 12 mg/m2; Ifosfamide 1200 mg/m2; Mercaptopurine 60 mg/m2; Methotrexate IV 1000 mg/m2; Methotrexate tab 20 mg/m2; Pegaspargase 2500 IU/m2; Procarbazine 60 mg/m2; Rituximab 375 mg/m2; Thiotepa 250 mg/m2; Thioguanine 60 mg/m2; Vinblastine 6 mg/m2; Vincristine 1.5 mg/m2.